Key result
CAVAL US-AHF trial evaluates ultrasound-guided therapy to reduce subclinical congestion at discharge.
Why the study?
Many patients hospitalised for acute heart failure are readmitted within 90 days due to persistent congestion at discharge, but optimal evaluation of decongestion remains undefined.
Does inferior vena cava and lung ultrasound-guided therapy reduce subclinical congestion at discharge in patients hospitalised for acute heart failure?
RCT (n=58)
Single-blind
Block randomisation, stratified by age and LVEF, 1:1 allocation
No
Does inferior vena cava and lung ultrasound-guided therapy reduce subclinical congestion at discharge in patients hospitalised for acute heart failure?
Answers are grounded in this paper and cite their sources.
The CAVAL US-AHF trial protocol details a strategy to use point-of-care ultrasound of the lungs and inferior vena cava to optimise decongestion in acute heart failure.
BACKGROUND: Between 25% and 30% of patients hospitalised for acute heart failure (AHF) are readmitted within 90 days after discharge, mostly due to persistent congestion on discharge. However, as the optimal evaluation of decongestion is not clearly defined, it is necessary to implement new tools to identify subclinical congestion to guide treatment. OBJECTIVE: To evaluate if inferior vena cava (IVC) and lung ultrasound (CAVAL US)-guided therapy for AHF patients reduces subclinical congestion at discharge. METHODS: CAVAL US-AHF is a single-centre, single-blind randomised controlled trial designed to evaluate if an IVC and lung ultrasound-guided healthcare strategy is superior to standard care to reduce subclinical congestion at discharge. Fifty-eight patients with AHF will be randomised using a block randomisation programme that will assign to either lung and IVC ultrasound-guided decongestion therapy ('intervention group') or clinical-guided decongestion therapy ('control group'), using a quantitative protocol and will be classified in three groups according to the level of congestion observed: none or mild, moderate or severe. The treating physicians will know the result of the test and the subsequent adjustment of treatment in response to those findings guided by a customised therapeutic algorithm. The primary endpoint is the presence of more than five B-lines and/or an increase in the diameter of the IVC, with and without collapsibility. The secondary endpoints are the composite of readmission for HF, unplanned visit for worsening HF or death at 90 days, variation of pro-B-type natriuretic peptide at discharge, length of hospital stay and diuretic dose at 90 days. Analyses will be conducted as between-group by intention to treat. ETHICS AND DISSEMINATION: Ethical approval was obtained from the Institutional Review Board and registered in the PRIISA.BA platform of the Ministry of Health of the City of Buenos Aires. TRIAL REGISTRATION NUMBER: NCT04549701.
No takes yet. Share an insight, caveat, or question.
Burgos et al. (2022) conducted an RCT in Acute Heart Failure (AHF) (n=58). Inferior vena cava (IVC) and lung ultrasound (CAVAL US)-guided therapy vs. Clinical-guided decongestion therapy (standard care) was evaluated on Presence of subclinical congestion at discharge (>5 B-lines and/or an increase in the diameter of the IVC, with and without collapsibility). This is a design and rationale paper describing the CAVAL US-AHF trial, which will evaluate whether ultrasound-guided therapy reduces subclinical congestion at discharge compared to standard care.
Synapse has enriched 10 related papers. Consider them for comparative context: